AMENDMENTS TO THE CLAIMS

Claims 1 to 23 (previously cancelled)

G/

Claim 24 (currently cancelled)

Claim 25 (previously added)

The method of claim 34 wherein the estrogen is an ester of estradiol.

Claim 26 (previously cancelled)

Claim 27 (currently cancelled)

Claim 28 (currently amended)

The method of claim 27 34 wherein the composition contains 1.5 mg of the free estradiol by daily is administered at a dose 1.5 mg per unit dose.

Claim 29 (currently amended)

The method of claim 27 34 wherein the composition contains 2mg of ester of estradiol is administered at a dose of 2 mg per unit dosage by daily dose.

Claim 30 (currently amended)

The method of claim 27 34 wherein the composition contains equine 0.625 of conjugated estrogen is administered at a dose of 0.625 mg per unit dosage.

Claims 31 and 32 (previously cancelled)

Claim 33 (currently amended)

The method of claim 34 wherein the <u>composition contains 2.5 mg of</u> nomegestrol acetate is administered at a dose of 2.5 mg per unit dosage by daily dose.

Claim 34 (currently amended)

A method of treating estrogenic deficiencies in <u>post menopausal</u> women while further avoiding the appearance of osteoporosis <u>and</u> withdrawal bleeding, and eardiovascular disease in post menopausal women without any androgenic effect, and no deleterious effects on blood vessels comprising continuously without interruption administering to said women, a <u>composition containing from eombination of 0.5</u> to 3 mg of an <u>estrogen estrogenic compound selected from the group consisting of free or esterified estradiol and 1.5 to 3.75 mg of nomegestrol acetate by daily dose.</u>

Claim 35 (currently cancelled)

Claim 36 (currently added)

The method of claim 34 wherein the composition is administered orally.

Claim 37 (currently added)

A method of treating estrogen deficiencies in post-menopausal women while further avoiding the appearance of osteoporosis and withdrawal bleeding, comprising continuously without interruption administering to said women, a composition containing from 0.5 to 3 mg of an estrogen selected among the conjugated equine estrogens and 1.5 to 3.75 mg of nomegestrol acetate by daily dose.

Claim 38 (currently added)

The method of claim 37 wherein the composition contains 0.625 mg of conjugated equine estrogens by daily dose.

Claim 39 (currently added)

The method of claim 37 wherein the composition contains 2.5 mg of nomegestrol acetate by daily dose.

Claim 40 (currently added)

The method of claim 37 wherein the composition is administered orally.